Procyrion successfully secures $57.7M in series E funding

Houston, February 5, 2024 (PRNewswire) -- Procyrion™, Inc., focused on enhancing patient outcomes in cardiac and renal care, has announced the successful closure of a $57.7 million series E funding round.  These funds are earmarked to further advance the ongoing DRAIN-HF pivotal IDE trial, regarding the Aortix™ percutaneous mechanical circulatory support (pMCS) device in addressing acute decompensated heart failure (ADHF) among patients who continue to experience congestion despite standard medical interventions (known as cardiorenal syndrome or CRS).

Read full article here.